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Introduction 
Mesenchymal stem cells (MSCs) are precursors of 
human and animal tissues. MSCs are detected within, 
and can be separated from, various sources including 
bone marrow (BM), adipose tissue (AT), cord tissue 
(CT), cord blood (CB), Wharton’s jelly (WJ), the pulp 
of milk teeth, the endometrium, and other sources. 
Modern researches have shown that MSCs process 
regenerative activities within damaged body tissues 
(Zakirova et al., 2017, 2019) and can be differentiated 
into four lines. This therapeutic effect is due to their 
ability to affect injured tissues with biologically active 
substances secreted by MSCs (Ragni et al., 2020).
The research into veterinary regenerative medicine has 
focused mainly on domestic and sporting animals, but 
a critical reading of the published results, combined 
with selected articles published for domestic animals, 
allows us to gain valuable insights about the future 
use of regenerative medicine in farming. Among all 
domesticated animals, cattle play a crucial role in the 
farming economy. There are several diseases, such as 
mastitis, lameness, and monomeric fractures to limb 
bones, which can negatively affect the production 
of meat and milk, in addition to the reduction in 
reproductive efficiency in cattle. For cows with high 
economic or genetic potential, these losses create 
significant costs for the owner, and the owner is obliged 
to use expensive and effective treatment methods to 
restore the animal’s health (Jean and Anderson, 2014).
According to literature data, osteoarthritis (OA) affects 
about 20% of dogs (Pigareva, 2016), and in horses, it 
is one of the most common causes of lameness. It is 
shown that approximately 33% of horses have cartilage 
injury associated with OA (Nifontov, 2009). Therefore, 
it is important to develop therapeutic approaches to 
stimulate the regeneration of hyaline tissue for better 
joint rehabilitation (Juneau et al., 2016). 
The aim of this review is to scrutinize the modern 
achievements of regenerative veterinary medicine in 
the treatment of joint injuries in animals.
The peculiarities of the structure and regeneration of 
cartilage tissue concerning MSC use
Articular cartilage is mainly composed of hyaline tissue 
which in itself is a specialized tissue present in most 
joints, providing low abrasion and amortization. It also 
provides a structural and biological barrier between the 
two bone surfaces, for an unimpeded, even range of 
motion in the joints. It should be noted that the cartilage 
is devoid of blood vessels, lymph nodes, and nerves 
and is generally split into the superficial, middle, and 
deep zones with calcified cartilage situated next to the 
subchondral bone (Duarte Campos, 2012) (Fig. 1).
Cartilage tissue mainly comprises 70%–80% of water, 
10%–15% of organic substances, and 4%–7% mineral 
salts. Collagen is found between 50% and 70% of the 
dry matter, which gives tensile strength, and also in 
proteoglycans, which provide functional resistance to 
compression (Francis et al., 2018). The thickness of 
articular cartilage depends on the type of joint and the 
age of the animal, in addition to the species type. The 
average thickness of knee cartilage in adult rabbits, 
sheep, dogs, goats, horses, and humans is 0.3, 0.4–0.5, 
0.6–1.3, 0.7–1.5, 1.5–2.0, and 2.2–2.5 mm, respectively 
(Frisbie et al., 2006). Due to its basic structure, 
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Abstract
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damaged hyaline cartilage has low regenerative 
abilities. This is a serious problem in orthopedics, 
both with and without treatment; cartilage injuries are 
filled with fibrous tissue, but this does not have the 
necessary specialized properties of hyaline cartilage 
and, therefore, compromises structure and function 
(Redman et al., 2005). Cartilage defects can penetrate 
throughout the entire thickness of the cartilage into the 
subchondral bone, or be limited to the cartilage itself 
(Gugjoo et al., 2016). Defects penetrating partially 
through the cartilage do not heal spontaneously due 
to the absence of a fibrin clump and, consequently, of 
reparative stem cells, although full thickness injuries 
heal spontaneously as they are filled in mechanically 
with structurally diminished fibrous tissues that do not 
integrate with native cartilage (Tiwary et al., 2014). 
However, one risk is that if the treatment is ineffective, 
the injury can lead to OA (Fig. 2). It should be noted that 
cartilage degeneration and inflammation are key signs 
of OA, which can affect the entire joint and cause pain, 
deformation, and loss of function (Toh et al., 2016).
Studies on animals show that MSCs obtained from adult 
tissues are prospective candidates for the treatment of 
injuries because they have low immunogenicity and 
high anti-inflammatory potential (Gao et al., 2015; 
Mount et al., 2015). In vivo studies using MSCs for 
cartilage therapy have been carried out on almost 
all domesticated species of mammals, including 
sheep, goats, dogs, horses, cattle, cats, and pigs. Both 
allogeneic and autogenic cells have been used in these 
studies. Researchers have noted that allogeneic MSCs 
transplanted once or several times are safe and do not 
cause any reactions from the immune system (Ardanaz 
et al., 2016; Vega et al., 2015). The cells are detected 
in vivo in the implantation zone even after 14 weeks 
(Feng et al., 2018). At present, it is recommended that 
MSCs be administered after anti-inflammatory therapy 
during the treatment of injured joint surfaces (Ando et 
al., 2012; Zayed et al., 2016).
Transplantation of MSCs in sheep and goats for 
cartilage injury treatment
At present, there are many articles devoted to the 
treatment of cartilage injury with MSCs originating 
from BM and AT, as they were extensively used to 
show the impact of MSCs transplantation in cartilage 
injury in sheep and goats which were used as models. 
The methods of administration of MSCs-AT and 
MSCs-BM are different but both intra-articular and 
systemic administration is recommended. However, all 
published studies have shown positive effects and an 
absence of complications in the animals following the 
introduction of MSCs (Caminal et al., 2014).
Some researchers recommend that to strengthen the 
regenerative potential of MSCs-BM, they should 
be pre-differentiated in the chondrogenic direction. 
In a model of surgically induced OA in sheep, pre-
differentiated MSCs-BM were introduced intra-
articularly and compared against a positive control 
group where intact MSCs-BM were introduced and 
negative control group animals were given a basal 
environment without cells. According to histological 
studies in the experimental group, the thickness and 
Fig. 1. Structure of cartilage tissue.
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quality of cartilage tissue were comparable to intact 
knee joint cartilage. In the positive control group, the 
researchers also noted positive effects from MSCs-
BM introduction, and in the negative control group, 
severe OA and meniscus damages were observed. 
Thus, a single intra-articular injection of intact or 
pre-differentiated in vitro MSCs-BM may slowdown 
the progression of OA in the sheep model, but pre-
differentiated cells showed better results, especially in 
the process of meniscus regeneration (Al Faqeh et al., 
2012).
Bornes et al. (2018) studied the effects of oxygen 
concentration on the regenerative potential of MSCs-
BM differentiated in the chondrogen direction. At the 
same time, native MSCs-BM was grown on scaffolds 
(cell matrices) made of hyaluronic acid. Before 
transplantation, MSCs were injected into the damaged 
joint and then placed in a differentiation medium and 
cultured at 21% oxygen (normoxia) or 3% (hypoxia) for 
4 days. Cells were not transplanted into animals in the 
control group having damaged joints. According to the 
results obtained from the experiments, the researchers 
concluded that when cells were cultured in vitro in a 
chondrogenic environment in hypoxic samples, the 
expression of aggrecan and type 2 of collagen increased. 
However, after in vivo implantation, the difference 
between normoxic and hypoxic samples on histological 
morphology was not detected, but in comparison with 
acellular controls in the two experimental groups, there 
were higher percentages of filling within injuries with a 
hyaline-like tissue (Bornes et al., 2018).
Abdalmula et al. (2017) studied the regenerative 
potential of MSCs which were obtained from the 
ovary of a sheep on a model of sheep monoarthritis. 
They received collagen-induced hock monoarthritis 
of the joint, and then animals were given intravenous 
MSCs derived from ovarian mesenchyma. As a result 
of the experiments, a positive regenerative effect of 
the selected MSCs was shown. The publication notes 
significant reductions in lameness, pain in the affected 
joints, and edema as compared to the animals in the 
control group. Besides, histological studies showed 
decreased cartilage erosion in the experimental group 
along with activation of the synovial stromal cells and 
angiogenesis. These effects were accompanied by a 
decrease in the infiltration of synovial tissues by CD4 
+ lymphocytes and CD14 + monocytes/macrophages. 
Within 3 days of induction in the MSCs injected in 
articular arthropathy animals, a significant decrease 
in the numbers of circulating neutrophils in the 
blood and the concentration of activin A in the blood 
plasma was observed. From the results obtained, it 
was concluded that MSCs isolated from the ovaries 
can soften the clinical signs of arthritis and reduce the 
concentration of certain inflammatory mediators in the 
blood responsible for the destruction of joint tissue 
(Abdalmula et al., 2017).
In a model of medial condyle defect of the femoral 
bone and trochlear notch in goats, MSCs-AT therapy 
and stromal vascular fraction (SVF) were used. The 
cells were seeded on a type I/III collagen scaffold 
and transplanted into animals. This procedure led to 
Fig. 2. Development of arthritis.
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stimulation and regeneration of cartilage compared to 
animals treated with scaffolds of cell-free collagen I/III. 
The researchers reported that there were no significant 
differences in the rate of regeneration between animals 
that received a collagen scaffold with MSCs-AT or 
SVF (Jurgens et al., 2013).
Regenerative therapy of cartilage injury in dogs by 
MSCs transplantation
In contrast to most studies in goats and sheep, dogs are 
not only used as model animals in preclinical research 
when developing MSCs therapies, but also as species-
specific treatments which are being developed for their 
own healthcare needs (Kazemi et al., 2017).
Kazemi et al. (2017) conducted a series of experiments 
on 12 adult dogs in which osteochondral defects were 
created on the medial condyles of the femoral bone, 
into which MSCs-BM mixed with a thrombocyte mass 
were placed. In control animals, the defect was not 
filled in. According to the results of the experiment, 
the use of autologous cultures of MSCs-BM with 
thrombocyte masses stimulated cartilage regeneration 
in dogs. Thrombocyte masses are rich with fibrin and 
create a suitable environment for proliferation and 
differentiation of MSCs by releasing endogenous 
growth factors that lead to the creation of hyaline-like 
reparative tissue (Kazemi et al., 2017).
The treatment of nine dogs with natural OA on the 
background of joint dysplasia also showed interesting 
results. The animals had not received any treatment 
for 2 months prior to a single intra-articular injection 
of autologous MSCs-AT. Observations noted over the 
ensuing 6 months showed that lameness and severe 
pain disappeared for 3 months, but thereafter the 
symptoms of the disease began to reappear (Vilar et 
al., 2014). However, studies conducted by Shah et al. 
(2018) have shown a positive effect of intravenous or 
intra-articular administration of MSCs in dogs with 
natural degenerative arthritis. Of the 203 dogs treated, 
88% had a significant reduction in clinical symptoms, 
while the remaining 12% had no reaction following cell 
administration. At the same time, it should be noted 
that the positive effects of the introduced MSCs-AT 
also correlated with the age of the animals. Significant 
improvements occurred in 90% of the younger dogs (up 
to 9 years old), which reduced to 60% of older dogs 
(Shah et al., 2018).
Intra-articular introduction of allogeneic MSCs in 0.5% 
hyaluronic acid to dogs suffering from elbow joint 
dysplasia and OA showed significant improvements in 
the condition of animals. Researchers noted the absence 
of lameness or reduction to just low-grade lameness for 
1 year. Control arthroscopy of the first group of dogs 
with the absence of lameness showed that the cartilage 
was restored. Histological analyses of the cartilage 
biopsy also confirmed that the regenerated cartilage 
was of the hyaline type. These results demonstrate 
that allogeneic MSCs-AT transplantation is a new, 
non-invasive, and highly effective therapeutic tool in 
the treatment of canine dysplasia of the elbow joint 
(Kriston-Pal et al., 2017).
The influence of species-specific MSCs umbilical cords 
of dogs was studied in animals with naturally occurring 
OA in the elbow joint. The presence of changes in 
the dog’s joint following treatment was confirmed by 
computer tomography. After collecting CB from dogs 
during planned cesarean section, MSCs were isolated 
from the umbilical cord and cultured in vitro. Each of 
the 28 dogs was given 7 million cells intra-articularly, 
and the 28 control dogs were given a saline solution. 
None of the dogs in either group developed worse 
lameness after treatment; therefore, none of the dogs 
had to be removed from the study. No adverse local 
side effects (increased pain, the appearance or increase 
of edema, and the appearance of secretions from the 
joints) were observed. The overall results of this study 
demonstrated an improvement of clinical signs over 6 
months in dogs treated with intra-articular injections of 
the umbilical cord. This fact is very attractive because 
other treatments of OA, such as corticosteroids, lead 
to risks associated with cytotoxicity, anaphylactic 
reactions, or septic arthritis (Kim et al., 2019).
Therapy of cartilage injury MSCs in horses
Most studies of MSC treatment in horses, whether 
preclinical or clinical, indicate incomplete regeneration 
of damaged horse cartilage, but MSCs therapy did 
produce a decrease in the severity of clinical signs in 
these animals (Broeckx Sarah et al., 2019; Kovac et al., 
2018). According to literature data, animal recovery 
was more effective when MSCs were introduced 
in the early stages of the disease but decreased 
when introduced at later stages (Wilke et al., 2007). 
Similar to autologous MSCs, a single intra-articular 
transplantation of allogeneic MSCs-BM also did not 
stir an immune response (Ardanaz et al., 2016), but 
repeated intra-articular transplantation led to adverse 
reactions following the introduction of allogeneic 
MSCs (Joswig et al., 2017).
MSCs-BM and AT have contributed toward the 
regeneration of damaged meniscus of horses, by 
restoring cartilage tissue (Gonzalez-Fernandez et al., 
2016). In this model of horse femoral knee disease, 
MSCs seeded in an autogenously self-polymerizing 
fibrin carrier were used with better results in the early 
stages compared to a cell-free fibrin carrier. In equids, 
improvements in arthroscopic parameters of the 
damaged horse meniscus cartilage were observed 30 
days after MSCs transplantation (Kovac et al., 2018). 
However, after a longer follow-up period (8 months), 
histological indicators in the group with MSCs were 
comparable to the control group (Wilke et al., 2007). 
Nevertheless, after 12 months, there was a slight 
improvement in clinical and histological indicators 
compared to the control group animals. In general, 
the use of MSCs-BM resulted in improved cartilage 
quality (McIIwraith et al., 2011). The ability of MSCs-
BM to stimulate the regeneration of cartilage tissue is 
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considered to be better than that of the SVF of adipose 
tissue (SVF-AT). The use of MSCs-BM in comparison 
with SVF-AT leads to better clinical, biochemical, and 
histological results in the treatment of horse joints with 
OA on day 70 following treatment (Frisbie et al., 2009).
In the search for effective treatments for degenerative 
joint disease, Broeckx Sarah et al. (2019) conducted 
a study involving 75 adult horses that had early signs 
of joint damage. Fifty animals were given intravenous 
allogeneic MSCs induced in the chondrogen direction 
with equine allogeneic plasma, and 25 horses were 
given a control drug having 0.9% NaCl. Long-term 
observation of animals after MSCs transplantation 
(1 year) showed that a significant number of horses 
subjected to cell therapy worked at the training level 
or returned to the previous level (Broeckx Sarah et al., 
2019).
Due to the presence of a considerable number of sources 
of MSCs, Zayed et al. (2018) conducted comparative 
studies of MSCs-BM and MSCs from synovial fluid 
(MSCs-SF) of horses in vitro. The results showed 
that MSCs-SF had similar proliferative activities to 
MSCs-BM and expressed the membrane markers 
CD29, CD44, and CD90, but demonstrated different 
chondrogenesis characteristics. In addition to this, 
MHC II was positively expressed in all MSCs, while 
in MSCs-BM the expression was negative. When both 
autologous and allogeneic MSCs were administered in 
vivo, an increment in the level of total protein and in 
the total number of nucleated cells was observed in the 
horse’s ankle joint. Therefore, further experiments to 
assess in vivo acute or chronic responses to allogeneic 
or autologous MSCs from various sources are necessary 
(Zayed et al., 2018).
Conclusion
The articular cartilage after damage tends to deteriorate 
every day due to its typical location and limited 
innate healing potential. With limited success of 
modern surgical methods, the inclusion of stem cells 
in regenerative drug therapy is intensively studied to 
ensure better rehabilitation of cartilage. Various stem 
cells derived from AT and BM MSCs are studied to 
assess their clinical use. This technology promises to 
develop a mechanically strong border between cartilage 
and cartilage, and includes mesenchymal condensation 
into cell bodies under the influence of growth factors. 
However, this method is yet to be tested in vivo (clinical 
conditions). The clinical use of MSCs has mainly 
been applied in dogs and horses, while in sheep and 
goats MSCs has mainly been studied in preclinical 
experimental models. MSCs chondrogenesis greatly 
varies in terms of cell sources, methods of cultivation, 
number of passages, number of implants required, and 
the inclusion of growth factors, and hence requires 
further research. In general, the best treatment is 
observed in the treatment of MSCs compared to the 
control. However, there are various problems with the 
treatment of MSCs, such as the lack of hyaline tissue 
regeneration, integration of the regenerated tissue 
matrix with the native cartilage or subchondral bone of 
the host, and its comparable effectiveness in all cases.
Thus, the use of the unique regenerative properties 
of MSCs from autologous AT, BM, CB, CT, and WJ 
can be considered fully effective, clinically applicable, 
safe, and dependable for improving the clinical results 
and therapeutic doses of injected cells.
Conflict of interest
The authors declare that there is no conflict of interest.
Acknowledgments
The reported study was funded by the RFBR (project 
number 20-016-00022) and by the Russian Government 
Program of Competitive Growth of Kazan Federal 
University.
References
Abdalmula, A., Dooley, L.M., Kaufman, C., 
Washington, E.A., House, J.V., Blacklaws, 
B.A., Ghosh, P., Itescu, S., Bailey, S.R. and 
Kimpton, W.G. 2017. Immuno-selected STRO-3þ 
mesenchymal precursor cells reduce inflammation 
and improve clinical outcomes in a large animal 
model of monoarthritis. Stem Cell Res. Ther. 8(1), 
22.
Al Faqeh, H., Nor Hamdan, B.M.Y., Chen, H.C., 
Aminuddin, B.S. and Ruszymah, B.H.I. 2012. 
The potential of intra-articular injection of 
chondrogenic-induced bone marrow stem cells to 
retard the progression of osteoarthritis in a sheep 
model. Exp. Gerontol. 47(6), 458–464.
Ando, W., Heard, B.J., Chung, M., Nakamura, N., 
Frank, C.B. and Hart, D.A. 2012. Ovine synovial 
membrane-derived mesenchymal progenitor cells 
retain the phenotype of the original tissue that was 
exposed to in-vivo inflammation: evidence for a 
suppressed chondrogenic differentiation potential 
of the cells. Inflamm. Res. 61(6), 599–608.
Ardanaz, N.V., Vazquez, F.J., Romero, A., Remacha, 
A.R., Barrachina, L., Sanz, A., Ranera, B., Vitoria, 
A., Albareda, J., Prades, M., Zaragoza, P., Martín-
Burriel, I. and Rodellar, C. 2016. Inflammatory 
response to the administration of mesenchymal 
stem cells in an equine experimental model: effect 
of autologous, and single and repeat doses of 
pooled allogeneic cells in healthy joints. BMC Vet. 
Res. 12(1), 65.
Bornes, T.D., Adesida, A.B. and Jomha, N.M. 2018. 
Articular cartilage repair with mesenchymal stem 
cells after chondrogenic priming: a pilot study. 
Tissue Eng. Part A. 24(9–10). 761–774.
Broeckx Sarah, Y., Seys, B., Suls, M., Vandenberghe, 
A., Marien, T., Adriaensen, E., Declercq, J., Van 
Hecke, L., Braun, G., Hellmann, K. and Spaas, 
J.H. 2019. Equine allogeneic chondrogenic induced 
mesenchymal stem cells are an effective treatment 
http://www.openveterinaryjournal.com
I. Ganiev et al. Open Veterinary Journal, (2021), Vol. 11(1): 128–134
133
for degenerative joint disease in horses. Stem Cells 
Dev. 28(6), 410–422.
Caminal, M., Fonseca, C., Peris, D., Moll, X., Rabanal, 
R.M., Barrachina, J., Codina, D., Garc, F., Cair, 
J.J., Godia, F., Pla, A. and Vives, J. 2014. Use of 
a chronic model of articular cartilage and meniscal 
injury for the assessment of long-term effects after 
autologous mesenchymal stromal cell treatment in 
sheep. New Biotechnol. 31(5), 492–498.
Duarte Campos, D.F., Drescher W., Rath, B., Tingart, 
M. and Fischer, H. 2012. Supporting biomaterials 
for articular cartilage repair. Cartilage. 3(3), 205–
221.
Feng, C., Luo, X., He, N., Xia, H., Lv, X., Zhang, X., 
Li, D., Wang, F., He, J., Zhang, L., Lin, X., Lin, L., 
Yin, H., He, J., Wang, J., Cao, W., Wang, R., Zhou, 
G. and Wang, W. 2018. Efficacy and persistence of 
allogeneic adipose-derived mesenchymal stem cells 
combined with hyaluronic acid in osteoarthritis 
after intra-articular injection in a sheep model. 
Tissue Eng. Part A. 24(3–4), 219–233.
Francis, S.L., Di Bella, C., Wallace, G.G. and Choong, 
P.F.M. 2018. Cartilage tissue engineering using 
stem cells and bioprinting technology-barriers to 
clinical translation. Front. surg. 5(70), 1–12.
Frisbie, D.D., Cross, M.W. and McIlwraith, C.W. 2006. 
A comparative study of articular cartilage thickness 
in the stifle of animal species used in human pre-
clinical studies compared to articular cartilage 
thickness in the human. Vet. Comp. Orthop. 
Traumatol. 19(03), 142–146.
Frisbie, D.D., Kisiday, J.D., Kawcak, C.E., Werpy, 
N.M. and McIlwraith, C.W. 2009. Evaluation 
of adipose-derived stromal vascular fraction or 
bone marrow-derived mesenchymal stem cells for 
treatment of osteoarthritis. J. Orthop. Res. 27(12), 
1675–1680.
Gao, Y., Zhu, Z., Zhao, Y., Hua, J., Ma, Y. and Guan, 
W. 2015. Multilineage potential research of bovine 
amniotic fluid mesenchymal stem cells. Int. J. Mol. 
Sci. 15(3), 698–710.
Gonzalez-Fernandez, M.L., Perez-Castrillo, S., 
Sanchez-Lazaro, J.A., Prieto-Fernandez, J.G., 
Lopez-Gonzalez, M.E., Lobato-Perez, S., Colaco, 
B.J., Olivera, E.R. and Villar-Suarez, V. 2016. 
Assessment of regeneration in meniscal lesions by 
use of mesenchymal stem cells derived from equine 
bone marrow and adipose tissue. Am J. Vet. Res. 
77(7), 779–788.
Gugjoo, M.B., Amarpal, Sharma, G.T., Aithal, H.P. and 
Kinjavdekar, P. 2016. Cartilage tissue engineering: 
role of mesenchymal stem cells along with growth 
factors and scaffolds. Indian J. Med. Res. 144, 339–
347.
Jean, G.S. and Anderson, D.E. 2014. Decision analysis 
for fracture management in cattle. Vet. Clin. North 
Am. Food Anim. Pract. 30(1), 1–10.
Joswig, A.J., Mitchell, A., Cummings, K.J., Levine, 
G.J., Gregory, C.A., Smith, R. and Watts, A.E. 2017. 
Repeated intra-articular injection of allogeneic 
mesenchymal stem cells causes an adverse response 
compared to autologous cells in the equine model. 
Stem Cell Res. Ther. 8(1), 42.
Juneau, C., Paine, R., Chicas, E., Gardner, E., Bailey, 
L. and McDermott, J. 2016. Current concepts 
in treatment of patellofemoral osteochondritis 
dissecans. Int. J. Sports Phys Ther. 11(6), 903–925.
Jurgens, W., Kroeze, R.J., Zandieh-Doulabi, B., 
Van Dijk, A., Renders, G.A., Smit, T.H., Van 
Milligen, F.J., Ritt, M.J. and Helder, M.N. 2013. 
One-step surgical procedure for the treatment of 
osteochondral defects with adipose-derived stem 
cells in a caprine knee defect: a pilot study. Biores. 
Open Access. 2(4), 315–325.
Kazemi, D., Shams Asenjan, K., Dehdilani, N. 
and Parsa, H. 2017. Canine articular cartilage 
regeneration using mesenchymal stem cells seeded 
on platelet rich fibrin. Bone Joint Res. 6(2), 98–107.
Kim, S.E., Pozzi, A., Yeh, J., Lopez-Velazquez, M., 
Au Yong, J.A., Townsend, S., Dunlap, A.E., 
Christopher, S.A., Lewis, D.D., Johnson, M.D. and 
Petrucci, K. 2019. Intra-articular umbilical cord 
derived mesenchymal stem cell therapy for chronic 
elbow osteoarthritis in dogs: a double-blinded, 
placebo-controlled clinical trial. Front. Vet. Sci. 6, 
474.
Kovac, M., Litvin, Y.A., Aliev, R.O., Zakirova, E.Y., 
Rutland, C.S., Kiyasov, A.P. and Rizvanov, A.A. 
2018. Gene therapy using plasmid DNA encoding 
VEGF164 and FGF2 genes: a novel treatment 
of naturally occurring tendinitis and desmitis in 
horses. Front. Pharmacol. 9, 978.
Kriston-Pal, E., Czibula, A., Gyuris, Z., Balka, G., 
Seregi, A., Sükösd, F., Süth, M., Kiss-Tóth, E., 
Haracska, L., Uher, F. and Monostori, É. 2017. 
Characterization and therapeutic application of 
canine adipose mesenchymal stem cells to treat 
elbow osteoarthritis. Can. J. Vet. Res. 81, 73–78.
McIIwraith, C.W., Frisbie, D.D., Rodkey, W.G., 
Kisiday, J.D., Werpy, N.M., Kawcak, C.E. and 
Steadman, J.R. 2011. Evaluation of intraarticular 
mesenchymal stem cells to augment healing of 
microfractured chondral defects. Arthroscopy. 27, 
1552–1561.
Mount, N.M., Ward, S.J., Kefalas, P. and Hyllner, J. 
2015. Cell-based therapy technology classifications 
and translational challenges. Philos. Trans. R. Soc. 
Lond. B. Biol. Sci. 370(1680), 1–16.
Nifontov, K.R. 2009. Morphofunctional characteristic 
and the ways of the destructive joint changes 
correction in the sports horses: experimental-
clinical investigation [in Russian]. PhD Dissertation 
of Veterinary Sciences. Moscow, Russia.
Pigareva, Yu.V. 2016. Clinical and morphological 
substantiation of efficiency of platelet-enriched 
http://www.openveterinaryjournal.com
I. Ganiev et al. Open Veterinary Journal, (2021), Vol. 11(1): 128–134
134
autoplasm use at aseptic dog osteoarthritis [in 
Russian]. PhD dissertation of veterinary sciences. 
Saratov, Russia.
Ragni, E., Perucca Orfei, C., De Luca, P., Mondadori, 
C., Viganò, M., Colombini, A. and De Girolamo, 
L. 2020. Inflammatory priming enhancers 
mesenchymal stromal cell secretome potential 
as a clinical product for regenerative medicine 
approaches through secret factors and EV-miRNAs: 
the example of joint disease. Stem Cell Res. Ther. 
11(1), 165.
Redman, S.N., Oldfield, S.F. and Archer, C.W. 2005. 
Current strategies for articular cartilage repair. Eur. 
Cell Mater. 9, 23–32.
Shah, K., Drury, T., Roic, I., Hansen. P., Malin, M., 
Boyd, R., Sumer, H. and Ferguson, R. 2018. 
Outcome of allogeneic adult stem cell therapy in 
dogs suffering from osteoarthritis and other joint 
defects. Hindawi. Stem Cells Int. 272, 1–7.
Tiwary, R., Amarpal, Aithal, H.P., Kinjavdekar, P., 
Pawde, A.M. and Singh, R. 2014. Effect of IGF-
1 and uncultured autologous bone-marrow-derived 
mononuclear cells on repair of osteochondral defect 
in rabbits. Cartilage 5, 43–54.
Toh, W.S., Brittberg, M., Farr, J., Foldager, C.B., 
Gomoll, A.H., Hui, J.H., Richardson, J.B., Roberts, 
S. and Spector, M. 2016. Cellular senescence in 
aging and osteoarthritis. Acta Orthop. 87(Sup363), 
6–14.
Vega, A., Martin-Ferrero, M.A., Del Canto, F., Alberca, 
M., Garcia, V., Munar, A., Orozco, L., Soler, R., 
Fuertes, J.J., Huguet, M., Sánchez, A. and García-
Sancho, J. 2015. Treatment of knee osteoarthritis 
with allogeneicbone marrow mesenchymal stem 
cells: arandomized controlled trial. Transplantation. 
99(8), 1681–1690.
Vilar, J.M., Batista, M., Morales, M., Santana, A., 
Cuervo, B., Rubio, M., Cugat, R., Sopena, J. and 
Carrillo, J.M. 2014. Assessment of the effect of 
intraarticular injection of autologous adipose-
derived mesenchymal stem cells in osteoarthritic 
dogs using a double blinded force platform analysis. 
BMC Vet. Res. 10(1), 143.
Wilke, M.M., Nydam, D.V. and Nixon, A.J. 2007. 
Enhanced early chondrogenesis in articular defects 
following arthroscopic mesenchymal stem cell 
implantation in an equine model. J. Orthop. Res. 
25(7), 913–925.
Zakirova, E.Yu., Valeeva, A.N., Aimaletdinov, 
A.M., Nefedovskaya, L.V., Akhmetshin, R.F., 
Rutland, C.S. and Rizvanov, A.A. 2019. Potential 
therapeutic application of mesenchymal stem cells 
in ophthalmology. Exp. Eye Res. 189, 107863.
Zakirova, E.Yu., Valeeva, A.N., Masgutov, R.F., 
Naumenko, E.A. and Rizvanov, A.A. 2017. 
Application of allogenic adipose-derived 
multipotent mesenchymal stromal cells from cat for 
tibial bone pseudoarthrosis therapy (Case Report). 
BioNanoScience. 7, 207–211.
Zayed, M.N., Adair, S., Ursini, T., Schumacher, J., 
Misk, N. and Dhar, M.S. 2018. Concepts and 
challenges in the use of mesenchymal stem cells as 
a treatment for cartilage damage in the horse. Res. 
Vet. Sci. 118, 317–323.
Zayed, M.N., Schumacher, J., Misk, N. and Dhar, M.S. 
2016. Effects of pro-inflammatory cytokines on 
chondrogenesis of equine mesenchymal stromal 
cells derived from bone marrow or synovial fluid. 
Vet. J. 217, 26–32.
